Switch theme
Sign up to access all valuation multiples
GuangYuYuan Chinese Herbal Medicine Co Ltd distributes pharmaceutical products. Its products include far plate turtle age wine bottle, niuhuang qingxin pills, boutique angong niuhuang wan, modified turtle age wine, ding kundan, and many more.
1996
3.1K+
LTM Revenue n/a
LTM EBITDA n/a
$1.1B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
GuangYuYuan Chinese has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, GuangYuYuan Chinese achieved revenue of $177M and an EBITDA of $20.2M.
GuangYuYuan Chinese expects next 12-month revenue of XXX and NTM EBITDA of XXX
See GuangYuYuan Chinese valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $177M | n/a | XXX | XXX | XXX |
| Gross Profit | $96.6M | $105M | XXX | XXX | XXX |
| Gross Margin | 55% | NaN% | XXX | XXX | XXX |
| EBITDA | $20.2M | n/a | XXX | XXX | XXX |
| EBITDA Margin | 11% | NaN% | XXX | XXX | XXX |
| Net Profit | -$7.8M | -$34.4M | XXX | XXX | XXX |
| Net Margin | -4% | NaN% | XXX | XXX | XXX |
| Net Debt | $23.5M | $16.0M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, GuangYuYuan Chinese's stock price is CNY 17 (or $2).
GuangYuYuan Chinese has current market cap of CNY 8.4B (or $1.2B), and EV of CNY 8.3B (or $1.1B).
See GuangYuYuan Chinese trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.1B | $1.2B | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, GuangYuYuan Chinese has market cap of $1.2B and EV of $1.1B.
GuangYuYuan Chinese's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate GuangYuYuan Chinese's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for GuangYuYuan Chinese and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $1.1B | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpGuangYuYuan Chinese's NTM/LTM revenue growth is n/a
GuangYuYuan Chinese's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $35K for the same period.
Over next 12 months, GuangYuYuan Chinese's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate GuangYuYuan Chinese's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for GuangYuYuan Chinese and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.1M | XXX | XXX | XXX | XXX |
| Opex per Employee | $35K | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 41% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 2% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 2% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 61% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
GuangYuYuan Chinese acquired XXX companies to date.
Last acquisition by GuangYuYuan Chinese was XXXXXXXX, XXXXX XXXXX XXXXXX . GuangYuYuan Chinese acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was GuangYuYuan Chinese founded? | GuangYuYuan Chinese was founded in 1996. |
| Where is GuangYuYuan Chinese headquartered? | GuangYuYuan Chinese is headquartered in China. |
| How many employees does GuangYuYuan Chinese have? | As of today, GuangYuYuan Chinese has 3.1K+ employees. |
| Is GuangYuYuan Chinese publicy listed? | Yes, GuangYuYuan Chinese is a public company listed on SHG. |
| What is the stock symbol of GuangYuYuan Chinese? | GuangYuYuan Chinese trades under 600771 ticker. |
| When did GuangYuYuan Chinese go public? | GuangYuYuan Chinese went public in 1996. |
| Who are competitors of GuangYuYuan Chinese? | Similar companies to GuangYuYuan Chinese include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of GuangYuYuan Chinese? | GuangYuYuan Chinese's current market cap is $1.2B |
| Is GuangYuYuan Chinese profitable? | Yes, GuangYuYuan Chinese is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
